The authors reported that 35.3% of patients with HR+/HER2- metastatic BC received ET as front-line treatment, and 17.2% of patients who had neither visceral metastasis nor progression on (neo)adjuvant ET wrongly received CT instead of ET (32). The gene discussed is HR; the disease is breast cancer.